Source link : https://www.newshealth.biz/health-news/novel-regimen-may-transform-pediatric-cystic-fibrosis-care/
TOPLINE: A 24-week phase 3 trial has found that once-daily vanzacaftor-tezacaftor-deutivacaftor is generally safe and well tolerated in children with cystic fibrosis aged 6-11 years. The treatment maintains normal baseline lung function while improving cystic fibrosis transmembrane conductance regulator (CFTR) function. METHODOLOGY: Researchers conducted a phase 3 trial across 33 clinical sites in eight countries […]
Author : News Health
Publish date : 2025-02-18 09:47:04
Copyright for syndicated content belongs to the linked Source.